Literature DB >> 24948714

Patient advocacy. 'Right to Try' laws bypass FDA for last-ditch treatments.

Kelly Servick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24948714     DOI: 10.1126/science.344.6190.1329

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  6 in total

1.  Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.

Authors:  Michael Hoerger
Journal:  Death Stud       Date:  2015-08-27

2.  Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.

Authors:  Denise Meyerson
Journal:  J Bioeth Inq       Date:  2017-06-20       Impact factor: 1.352

3.  Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.

Authors:  Jonathan P Jarow; Steven Lemery; Kevin Bugin; Sean Khozin; Richard Moscicki
Journal:  Ther Innov Regul Sci       Date:  2016-11       Impact factor: 1.778

Review 4.  From bench to FDA to bedside: US regulatory trends for new stem cell therapies.

Authors:  Paul S Knoepfler
Journal:  Adv Drug Deliv Rev       Date:  2014-12-07       Impact factor: 15.470

Review 5.  Reflections on translation: Views of participants in a multisite Canadian CCSVI clinical trial.

Authors:  Shelly Benjaminy; Cody Lo; Judy Illes; Anthony Traboulsee
Journal:  Neurol Clin Pract       Date:  2018-06

6.  An Analysis of Sponsors/Collaborators of 69,160 Drug Trials Registered with ClinicalTrials.gov.

Authors:  Shruthi Muralidharan Keezhupalat; Ankeet Naik; Saurabh Gupta; Raghunathan Srivatsan; Gayatri Saberwal
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.